Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 18/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1518385 | 0.84 | REN (0.47) | RENKCNH2CYP3A4 | |
| SCHEMBL1072075 | 0.83 | REN (0.54) | RENKCNH2CYP3A4 | |
| SCHEMBL12525830 | 0.82 | REN (0.42) | RENKCNH2CYP3A4 | |
| SCHEMBL15417882 | 0.82 | REN (0.42) | RENKCNH2CYP3A4 | |
| SCHEMBL4525755 | 0.81 | CETP (0.39) | RENKCNH2CETP | |
| SCHEMBL1073071 | 0.80 | REN (0.56) | RENKCNH2CYP3A4 | |
| SCHEMBL1073744 | 0.79 | REN (0.51) | RENKCNH2CYP3A4 | |
| SCHEMBL1080226 | 0.78 | REN (0.51) | RENKCNH2CYP3A4 | |
| SCHEMBL2814031 | 0.78 | REN (0.64) | REN | |
| SCHEMBL4523432 | 0.78 | CETP (0.38) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889714-B2 | 3,4-substituted piperidine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-06-23 | — | — | US | disclosed |
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2274295-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, ACE2 | REN 1/4885KCNH2 320/4885CYP3A4 99/4885 |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 585/4885CYP3A4 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.